Observing Changes in Inflammation and Fibrosis Markers in Adults Undergoing Catheter Ablation for Atrial Fibrillation

What this Trial Is About

This observational study focuses on patients with paroxysmal or persistent atrial fibrillation AF undergoing catheter ablation. The main aim is to explore how inflammation markers relate to local fat deposits, clinical risk factors, and changes after AF ablation. Researchers want to better understand the link between inflammation and heart tissue changes in this condition. The study involves collecting blood samples at various times to measure inflammation and fibrosis markers such as Interleukin 6, N-terminal propeptide of procollagen type 1 P1NP, chitinase-3-like protein 1 YKL-40, tumor necrosis factor TNF-alpha, GlycA, proprotein convertase subtilisinkexin type 9, and omega-3 fatty acids. These markers are analyzed to assess changes before and after the ablation procedure. Participants will be monitored over one year to evaluate reductions in inflammation and improvements in clinical outcomes including arrhythmia recurrence. The study includes clinical evaluations, blood tests for biomarkers, and electroanatomical mapping to assess atrial fibrosis. The research team will track how inflammation levels correspond with heart tissue changes and patient recovery during this period.

Change in Inflammatory State in Patients Undergoing Transcatheter Ablation of Atrial Fibrillation